NASDAQ:CPRX

Catalyst Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CPRX

*Your capital is at risk

$31.27

+0 (+0%)

At Close: Jun 02, 2026

Catalyst Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 66.70. In total, the insiders bought 1.61M and sold 220.4K CPRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	66.70
● Buy	1.61M shares
● Sell	220.4K shares
79% Buy Activity Moderate Positive Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 66.7. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (79% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 21, 2025 Buy	Common stock, par value $0.001 per share M-Exempt	Miller Steve Chief Op. & Scientific Officer	Officer	8 267 Value: $192.5K
Nov 21, 2025 Buy	Restricted Stock Units M-Exempt	Kalb Michael Wayne Executive Vice President & CFO	CEO / President	6 894 Value: $160.5K
Nov 21, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Kalb Michael Wayne Executive Vice President & CFO	CEO / President	6 894 Value: $160.5K
Nov 21, 2025 Sell	Common Stock, par value $0.001 per share F-InKind	Kalb Michael Wayne Executive Vice President & CFO	CEO / President	2 485 Value: $0
Nov 21, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Tierney David S Director	Director	947 Value: $22.0K
Nov 21, 2025 Buy	Restricted Stock Units M-Exempt	Harper Molly Director	Director	947 Value: $22.0K
Nov 21, 2025 Buy	Common Stock, par value $0.001 per share M-Exempt	Harper Molly Director	Director	947 Value: $22.0K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Daly Richard J President And CEO	CEO / President	381 948 Value: $8.70M
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	34 921 Value: $795.2K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Mcenany Patrick J Chairman Of Board Of Directors	CEO / President	10 540 Value: $240.0K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Tierney David S Director	Director	18 115 Value: $412.5K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Kalb Michael Wayne Executive Vice President & CFO	CEO / President	39 701 Value: $904.0K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Thompson Tamar Director	Director	18 115 Value: $412.5K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Thompson Tamar Director	Director	5 468 Value: $124.5K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Russo Gregg Chief Hr Officer	Officer	20 531 Value: $467.5K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Russo Gregg Chief Hr Officer	Officer	6 197 Value: $141.1K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Sundaram Preethi Chief Strategy Officer	Officer	32 257 Value: $734.5K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Sundaram Preethi Chief Strategy Officer	Officer	106 873 Value: $2.43M
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Miller Steve Chief Op. & Scientific Officer	Officer	47 826 Value: $1.09M
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Miller Steve Chief Op. & Scientific Officer	Officer	158 454 Value: $3.61M
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Kalb Michael Wayne Executive Vice President & CFO	CEO / President	131 536 Value: $3.00M
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Tierney David S Director	Director	5 468 Value: $124.5K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Harper Molly Director	Director	5 468 Value: $124.5K
Nov 20, 2025 Buy	Options to purchase common stock A-Award	Harper Molly Director	Director	18 115 Value: $412.5K
Nov 20, 2025 Buy	Restricted Stock Units A-Award	Daly Richard J President And CEO	CEO / President	115 283 Value: $2.62M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CATALYST PHARMACEUTICALS

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop...

Read Full Profile Here